N@N

Market Maker Surveillance Report. OXGN, TSPT, SOMX, FINMY, TLON, SQNS, Winning Stocks With Lowest Price Friction For Wednesday

September 14, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4069 companies with "abnormal" market making, 3963 companies with positive Friction Factors and 2249 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Wednesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. OXIGENE INC (NASDAQ:OXGN), TRANSCEPT PHARMACEUTICALS IN (NASDAQ:TSPT), SOMAXON PHARMACEUTICALS INC (NASDAQ:SOMX), FINMECCANICA SPA-UNSPN ADR (OTC:FINMY), TALON THERAPEUTICS INC (OTCBB:TLON), (NYSE:SQNS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     OXGN       $0.250       20.00%       2,073,422       53.03%       1,828,280       46.76%       245,142         9,806   
     TSPT       $0.880       29.33%       368,394         56.63%       268,368         41.25%       100,026         1,137   
     SOMX       $0.200       20.00%       691,992         50.81%       669,848         49.19%       22,144          1,107   
     FINMY      $0.590       19.47%       55,519          42.90%       47,902          37.02%       7,617           129     
     TLON       $0.140       15.91%       148,215         65.07%       57,580          25.28%       90,635          6,474   
     SQNS       $3.080       69.53%       2,318,700       32.55%       2,236,273       31.40%       82,427          268     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows OXGN with a dollar gain Wednesday of $0.25000 and a Friction Factor of 9,806 shares. That means that it only took 9,806 more shares of buying than selling to move OXGN higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

OXIGENE INC (NASDAQ:OXGN) - OXiGENE, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat cancer and eye diseases in the United States. It primarily focuses on the development of product candidates that disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival, as well as associate with visual impairment in various ophthalmological diseases and conditions. The companys products include ZYBRESTAT, which is in FALCON Trial - Phase II randomized controlled study for the treatment of 1st-line non-small cell lung cancer, as well as in Phase II Simon two-stage design study for the treatment of platinum-resistant ovarian cancer; and OXi4503 that is in Phase I dose-escalation study and Phase Ib dose-ranging study for the treatment of refractory solid tumors hepatic tumors. Its products also include ZYBRESTAT for ophthalmology, which is in phase II randomized, double-masked, placebo-controlled, and single-dose study for proof-of-mechanism study in polypoidal choroidal vasculopathy. OXiGENE has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology, and OXi4503. The company was founded in 1988 and is headquartered in South San Francisco, California.

TRANSCEPT PHARMACEUTICALS IN (NASDAQ:TSPT) - Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in neuroscience. Its principal product includes Intermezzo, a sublingual low dose formulation of zolpidem that is being developed as a sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. The company has collaboration agreement with Purdue Pharmaceutical Products L.P. to commercialize Intermezzo in the United States. Transcept Pharmaceuticals, Inc. is headquartered in Point Richmond, California.

SOMAXON PHARMACEUTICALS INC (NASDAQ:SOMX) - Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the in-licensing, development, and commercialization of proprietary branded products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Its principal product Silenor (doxepin) has been approved by the United States Food and Drug Administration for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Solana Beach, California.

FINMECCANICA SPA-UNSPN ADR (OTC:FINMY) - Finmeccanica SpA, together with its subsidiaries, engages in the helicopters, defense, electronics and security, aeronautics, space, defense systems, energy, and transportation businesses. It manufactures tactical airlifters, combat aircraft, and unmanned air vehicles for civil and military applications; produces training aircraft with related support services; and provides aircraft modification and overhaul services. The company also designs and develops helicopters and tiltrotors for civil and military use; and designs, develops, and manufactures positioning, telecommunications, earth observation, and remote sensing satellites for civil and military use, as well as missile systems, torpedoes, naval artillery, and armored vehicles. In addition, it offers defense and security electronics, including avionics, and military and secure communications systems; systems for homeland protection, defense systems, air, airport, and coastal traffic management; and systems and solutions for automation, security, transports, defense, space, and information technology. Further, the company offers systems and components for power generation for public sector agencies, independent producers, and industrial customers; and designs, develops, and manufactures rolling stock, transport solutions, and railway signaling systems. It has operations primarily in Italy, the United Kingdom, rest of Europe, and North America. The company has joint venture agreements with BAE Systems Plc, EADS NV, Thales SA, and Tripoli. Finmeccanica SpA was founded in 1948 and is based in Rome, Italy.

TALON THERAPEUTICS INC (OTCBB:TLON) - Talon Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. Its lead product candidate, Marqibo (vincristine sulfate liposomes injection), is a targeted Optisome encapsulated formulation product candidate, which is in the development for the treatment of acute lymphoblastic leukemia and lymphomas. The companys product candidates also include Menadione Topical Lotion, a supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, a type of anti-cancer agent used in the treatment of cell lung cancer, pancreatic, colorectal, breast, and head and neck cancer; and Brakiva (topotecan liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, including small cell lung cancer and ovarian cancer. In addition, its development stage product consists of Alocrest (vinorelbine liposomes injection), a targeted Optisome encapsulated formulation product candidate for the treatment of solid tumors, such as non-small-cell lung cancer. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. The company was formerly known as Hana Biosciences, Inc. and changed its name to Talon Therapeutics, Inc. in December 2010. Talon Therapeutics, Inc. was founded in 2002 and is based in South San Francisco, California.

(NYSE:SQNS) -

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net